MAP2K7 and melanoma: Here we confirmed that the inhibition of MAPK leads to the modulation of several molecules that affect NK immune response and that BRAF-mutant melanoma cell lines, sensitive to vemurafenib, respond to the combination of BRAF and MEK inhibitors in a very similar manner to single inhibition.